Genentech, Inc. v. Sandoz Inc.

  1. December 22, 2022

    Fed. Circ. Won't Revive Genentech Lung Disease Patents

    A Delaware federal judge rightly invalidated claims in a Roche unit's patents for a lung disease drug it paid $8 billion to acquire and properly held that a Novartis unit's generic version doesn't infringe, the Federal Circuit said Thursday.

  2. October 04, 2022

    Fed. Circ. Casts Doubt On Bid To Revive Lung Drug IP Fight

    Two judges in a Federal Circuit panel on Tuesday seemed unpersuaded by an argument from Roche unit Genentech Inc. that a Delaware federal judge wrongly let Sandoz Inc. off the hook for infringing patents on the pulmonary fibrosis drug Esbriet.

  3. September 29, 2022

    IP Forecast: Philip Morris Looks To Snuff Out ITC Ban

    Two of the largest tobacco companies in the world head to the Federal Circuit to fight over a ban R.J. Reynolds won at the U.S. International Trade Commission that blocked Philip Morris from importing IQOS-branded heated tobacco products into the U.S. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.

  4. May 09, 2022

    Fed. Circ. Won't Block Generic Lung Drug During Appeal

    The Federal Circuit has refused to block Sandoz from launching a generic version of pulmonary fibrosis drug Esbriet, rejecting Genentech's bid for an injunction during an appeal in litigation involving the companies.